Galsulfase

Nature Reviews Drug Discovery

Volumn 5, Issue 2, 2006, Pages 101-102

  Hopwood, John J ^a   Bate, Guy ^b   Kirkpatrick, Peter ^c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; ALGLUCOSIDASE ALPHA; CHAPERONE; DERMATAN SULFATE; ELAPRASE; GALSULFASE; IDUSULFASE; IMIGLUCERASE; LARONIDASE; LYSOSOME ENZYME; MIGLUSTAT; N ACETYLGALACTOSAMINE 4 SULFATASE; ORPHAN DRUG; PLACEBO; RECOMBINANT ENZYME; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW TRANSPLANTATION; CHO CELL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; EARLY DIAGNOSIS; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE COST; HEART VALVE; HUMAN; HUNTER SYNDROME; LYSOSOME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MORTALITY; NEWBORN SCREENING; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECOMBINANT DNA TECHNOLOGY; SKELETON MALFORMATION; SOFT TISSUE DEFECT; ANIMAL; FEMALE; GENETICS; HAMSTER;

ANIMALS; CHO CELLS; CRICETINAE; FEMALE; HUMANS; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS;

EID: 33645058934     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1962     Document Type: Article

References (13)

1. Desnick, R. J. & Schuchman, E. H. Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders. Nature Rev. Genet. 3, 954-966 (2002).
2. Neufeld, E. F. & Muenzer, J. in The Metabolic and Molecular Bases of Inherited Disease (eds Scriver, C. et al.) 3421-3452 (McGraw-Hill, New York, 2001).
3. Anson, D. S. et al. Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. Biochem. J. 284, 789-794 (1992).
4. Crawley, A. C. et al. Enzyme replacement therapy in a feline model of Maroteaux-Larry syndrome. J. Clin. Invest. 97, 1864-1873 (1996).
5. Crawley, A. C. et al. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J. Clin. Invest. 99, 651-662 (1997).
6. FDA labelling information [online], (2005).
7. Harmatz, P. et al. Enzyme replacement therapy in mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). J. Pediatr. 144, 574-580 (2004).
8. Kakkis, E. et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 83, 163-174 (2004).
9. Meikle, P. J. et al. Newborn screening for lysosomal storage disorders: evaluation of protein profiling. J. Inherit. Met. Dis. 28, 14 (2005).
10. Li, Y. et al. (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin. Chem. 50, 1785-1796 (2004).
11. Meikle, P. J., Hopwood, J. J. & Clague, A. E. Prevalence of lysosomal storage disorders. JAMA 281, 249-254 (1999).
12. Genzyme data (2006).
13. Shire data (2006).